NIAID has been at the forefront of cutting-edge biomedical research for decades. The work performed in its labs has furthered the understanding of the immune system and led to significant advances in the fields of immunology and infectious disease research. But it's a long path from basic scientific discoveries to approved vaccines, treatments, or diagnostic tools. NIAID is constantly pursuing collaborations with industry and academia to develop its technologies and materials into products that improve public health. The Technology Transfer and Intellectual Property Office facilitates collaborative relationships between NIAID investigators and the broader scientific community.
Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
Arsenical Compounds as Therapeutics for Inflammatory Diseases
Anthrax Fusion Toxins With Improved Ability To Penetrate Cells
Multi-Specific Chimeric Antigen Receptors Against HIV
Complete list of Recent Licensing and Collaboration Opportunities
United States patent US 8,568,739 was issued on Oct. 29, 2013, for Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses. NIAID inventors: Alexander Pletnev, Ph.D., D.Sci.
NIAID and Gilead Sciences, Inc., signed a CRADA to study the safety and efficacy of Gilead's proprietary compounds including GS7977, GS5885, and GS9669 to treat hepatitis C/HIV co-infection and HCV infection in hard-to-treat populations and identification of the clinical and biological correlates associated with treatment response. NIAID principal investigator: Shyamasundaran Kottilil M.D., Ph.D.
Complete list of Technology Development Recent Happenings
Last Updated June 18, 2014